Y-Intercept (HK)
CAI icon

Y-Intercept (HK)’s Caris Life Sciences CAI Stock Holding History

Y-Intercept (HK)’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-46,068
Closed -$821K – 2220
2026
Q2 		$821K Buy
+46,068
New +$825K 0.02% 1123

Other funds holding CAI

Zevenbergen Capital Investments
Zevenbergen Capital Investments Edmonds, Washington $4.37B AUM 52.9% 1-Year Est. Return
Pembroke Management
Pembroke Management Montreal, Quebec, Canada $809M AUM 17.64% 1-Year Est. Return
E. Ohman J:or Asset Management
E. Ohman J:or Asset Management Stockholm, Sweden $4.47B AUM 27.58% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Renaissance Capital
Renaissance Capital Stamford, Connecticut $145M AUM 53.16% 1-Year Est. Return
Krilogy Financial
Krilogy Financial St. Louis, Missouri $3.66B AUM 22.28% 1-Year Est. Return
HB Wealth Management
HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return
Perigon Wealth Management
Perigon Wealth Management San Francisco, California $6.5B AUM 20.72% 1-Year Est. Return
Courier Capital
Courier Capital Buffalo, New York $2.02B AUM 16.74% 1-Year Est. Return
City Center Advisors LLC
City Center Advisors LLC Troy, Michigan $131M AUM 24.02% 1-Year Est. Return

Y-Intercept (HK)'s CAI Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Caris Life Sciences (CAI) in Q3 2026, closing a stake of 46,068 shares — an estimated $821K sold.

Y-Intercept (HK) first reported a position in CAI in Q2 2026 and held it in 1 quarter. The position peaked at $821K in Q2 2026. 47 funds tracked by Wall St. Rank hold CAI as of Q3 2026.

  • Y-Intercept (HK) reported no remaining Caris Life Sciences position as of Q3 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 46,068 Caris Life Sciences shares in Q3 2026, an estimated $821K.
  • Y-Intercept (HK) first reported a position in Caris Life Sciences in Q2 2026 and held it in 1 quarter.
  • Y-Intercept (HK)'s Caris Life Sciences position peaked at $821K in Q2 2026.
  • 47 funds tracked by Wall St. Rank held Caris Life Sciences as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.